Participated · Seed · May 2026

Urologic Health is developing the niu™ System, a non-invasive platform designed to capture bladder activity and convert it into clinically meaningful diagnostic data without catheterization. The company has completed early feasibility studies that it says demonstrate clinically meaningful capture of bladder activity and is pursuing an FDA 510(k) regulatory pathway. The niu™ System is not yet approved for sale in the United States and is currently limited to investigational use. Urologic Health was co-founded by Adam Yaacov and Dr. Noam Omer and was incubated at the MEDX Xelerator (now EdgeLabs); it operates within the Edge Medical Ventures portfolio with operations in the U.S. and Israel. Following an $11 million seed financing, the company plans to use proceeds for clinical validation, product and manufacturing development, initial U.S. commercialization efforts, and establishment of its Jersey City headquarters.

Participated · Series A · Jul 2025

Cooler Heads develops Amma™, which the company describes as the only FDA‑cleared portable scalp cooling system, designed to help chemotherapy patients keep their hair and preserve privacy. Amma provides infusion centers and patients flexibility to scalp cool where it is most convenient, using a continuous cooling system that eliminates the need for dry ice or frequent cap changes. By cooling the scalp before, during, and after chemotherapy, Amma reduces blood flow to hair follicles to shield them from chemotherapy drugs and prevent hair loss. The company was founded by breast cancer survivor Kate Dilligan, who serves as CEO. Cooler Heads positions Amma as a low‑friction therapy for infusion centers and notes the American Medical Association’s decision to elevate scalp cooling reimbursement codes to Category I starting January 2026 as creating momentum. The business also offers evidence‑based products, content, and services to help patients manage treatment side effects. Cooler Heads develops Amma, an FDA-cleared scalp-cooling medical device intended to help cancer patients undergoing chemotherapy preserve their hair. The company positions its product as dramatically less expensive and easier to use than existing scalp-cooling solutions. Founder and CEO Kate Dilligan, a cancer survivor, built an early prototype herself and pursued clinical relationships before raising institutional capital. Cooler Heads announced FDA clearance and said it has signed multiple commercial partnerships and will begin serving patients in Q1 2022. The company highlighted its mission-driven focus on patient dignity and plans to push commercialization to make scalp cooling broadly accessible. Cooler Heads has been backed by several venture investors and industry leaders and has participated in accelerators and medtech competitions.

Participated · Series A · Apr 2025

SecondWave Systems is a clinical-stage medical device company focused on creating noninvasive ultrasound therapies for inflammatory disorders. Its flagship product, the SecondWave MINI™, is a first-of-its-kind wearable device that uses proprietary ultrasound technology to stimulate the spleen and modulate inflammatory responses. The company aims to offer patients and physicians a new option for managing acute and chronic inflammation, including conditions such as rheumatoid arthritis. Current efforts center on clinical studies to validate the platform’s safety and efficacy across multiple inflammatory indications. Proceeds from its ongoing financing will accelerate product development, clinical trials, and eventual commercialization. Based in St. Paul, Minnesota, SecondWave collaborates with an experienced syndicate of medical-technology investors to bring its therapy to market. No revenue or user metrics have been disclosed, reflecting the company’s pre-commercial stage of operations.

Led · Series B · Jul 2023

Liberate Medical is a medical device company based in Crestwood, Ky that develops neuromuscular electrical stimulation technology to improve care and reduce costs for patients with pulmonary disorders. Its lead product, VentFree Respiratory Muscle Stimulator, is the only non-invasive, breath-synchronized neuromuscular electrical stimulator intended to prevent expiratory muscle atrophy in mechanically ventilated patients. VentFree has FDA Breakthrough Device Designation, FDA Emergency Use Authorization, and CE marking in the European Union, and follows two successful pilot randomized controlled trials in Europe and Australia. The company plans to use Series B proceeds to support the pivotal PREVENT trial, which aims to show VentFree reduces duration of invasive mechanical ventilation in patients at risk of being difficult to wean. Liberate intends that reduced ventilation time will lower risks such as hospital-acquired infections, deteriorated quality of life, and death. The funding is also intended to support preparations for FDA regulatory clearance and a full commercial launch of VentFree.

Participated · Series C · Mar 2022

Podimetrics developed the FDA-cleared SmartMat™, an easy-to-use at-home mat that detects temperature changes in patients’ feet and alerts the company’s clinical and patient support team. The SmartMat is paired with integrated clinical care services aimed at preventing amputations in complex diabetic patients. Podimetrics partners with regional and national health plans and at-risk providers, including the Veterans Health Administration, to drive adoption. The company reports high patient engagement rates and emphasizes keeping vulnerable populations healthy in their homes. Founded in 2011 and based in Somerville, Mass., and Menlo Park, Calif., Podimetrics plans to expand its commercial operations. It received growth capital to support that expansion. Podimetrics develops the FDA-cleared SmartMat™ and integrated clinical care services aimed at preventing amputations and other complications in complex diabetic patients. The company partners with regional and national health plans and at-risk providers, including the Veterans Health Administration, to deliver its monitoring and care services. Podimetrics plans to use the new funding to hire and build out product development and research teams. It also intends to expand the breadth of services delivered by its nurse support team. The company was founded in 2011 by Jon Bloom, MD, who serves as CEO, and is based in Somerville, Massachusetts. The article does not disclose operating metrics such as revenue or user counts. Podimetrics offers a remote physiologic monitoring solution centered on its FDA-cleared SmartMat, which patients stand on for 20 seconds daily so data are sent to a care management team. The company partners with payers and at-risk providers, including the Veterans Health Administration, and its services are used in more than 40 VA medical facilities. Podimetrics reports more than 300% growth in the first half of 2020 versus the prior year and earns high patient engagement rates. The SmartMat is manufactured in Massachusetts and has the American Podiatric Medical Association Seal of Approval. Podimetrics was founded in 2011 by a physician and engineers from MIT and Harvard and is headquartered in Somerville, MA. With new advisory board additions, the company is expanding its commercial presence to reach more at-risk patients in the VHA and private payer markets. Podimetrics offers a preventive care solution for diabetic foot ulcers consisting of an FDA-cleared, cellular-connected SmartMat paired with a care management team that triages concerning findings. High-risk patients place their feet on the mat for about 20 seconds daily and the device automatically transmits data for review. The company delivers this service on behalf of payers and at-risk providers. Podimetrics closed a $13.4M Series B to fund its growth. Management intends to use the proceeds to accelerate adoption within the Veterans Affairs health care system and among commercial payers nationwide. The company is focused on scaling deployment and payer relationships to expand monitoring and early intervention. Podimetrics builds a bathroom-mat sensor system that scans patients' feet, sends blood-flow data to the cloud, and uses algorithms to analyze longitudinal trends and left-right comparisons to detect pre-ulcers. When the algorithms detect a developing ulcer, the system sends alerts to the patient and their doctor to prompt early intervention. The device takes about 30 seconds to use each day. The company graduated from Rock Health’s healthcare accelerator. Podimetrics says it will use recent investment proceeds to develop additional products to help people with diabetes. Since October the company has raised $2.5 million, per the article.